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Osteosarcoma (OS) is the most common primary type 
of cancer that develops in the bone and accounts for 
20% of all primary osseous neoplasms [1, 2]. Most OS 
occur in young adults and children and usually develop 
in areas where the bone is rapidly growing such as the 
proximal tibia, distal femur, and proximal humerus [3]. 
Metastatic spread of OSs preferentially occurs in the lungs 
which is correlated with poor survival and is seen in 20% 
of patients with OS [4, 5]. Over the past 20 years, treat-
ment of OS has advanced considerably due to the increased 
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Abstract
Tumor hypoxia is a major cause of treatment failure for a variety of malignan-
cies. However, hypoxia also leads to treatment opportunities as demonstrated 
by the development of compounds that target regions of hypoxia within tumors. 
Evofosfamide is a hypoxia- activated prodrug that is created by linking the 
hypoxia- seeking 2- nitroimidazole moiety to the cytotoxic bromo- 
isophosphoramide mustard (Br- IPM). When evofosfamide is delivered to hypoxic 
regions of tumors, the DNA cross- linking toxin, Br- IPM, is released leading to 
cell death. This study assessed the anticancer efficacy of evofosfamide in com-
bination with the Proapoptotic Receptor Agonists (PARAs) dulanermin and 
drozitumab against human osteosarcoma in vitro and in an intratibial murine 
model of osteosarcoma. Under hypoxic conditions in vitro, evofosfamide co-
operated with dulanermin and drozitumab, resulting in the potentiation of 
cytotoxicity to osteosarcoma cells. In contrast, under the same conditions, pri-
mary human osteoblasts were resistant to treatment. Animals transplanted with 
osteosarcoma cells directly into their tibiae developed mixed osteosclerotic/os-
teolytic bone lesions and consequently developed lung metastases 3 weeks post 
cancer cell transplantation. Tumor burden in the bone was reduced by evofos-
famide treatment alone and in combination with drozitumab and prevented 
osteosarcoma- induced bone destruction while also reducing the growth of pul-
monary metastases. These results suggest that evofosfamide may be an attractive 
therapeutic agent, with strong anticancer activity alone or in combination with 
either drozitumab or dulanermin against osteosarcoma.
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efficacy of conventional chemotherapeutic agents. The type, 
combination as well as the doses of chemotherapeutic 
agents given as well as the sensitivity of the tumor cells 
determine the patients’ response to treatment. Despite 
these advances in treatment, drug resistance still remains 
a problem [6]. In addition, conventional chemotherapeutic 
drugs have a significant impact on normal bone health, 
leading to a greater risk of developing osteoporosis and 
myelosuppression due to toxicities in the bone marrow 
[7, 8].
The characteristics of bone lesions caused by OS are 
based on their radiologic appearance which can be either 
osteoblastic (osteosclerotic), osteolytic, or a combination 
of both [9]. Osteolysis is common with OS and is caused 
by the bone resorbing activity of osteoclasts [10, 11]. 
Tumor growth is stimulated by factors released from the 
bone and in turn tumor cells produce factors that stimu-
late osteoclastic bone resorption, resulting in a mutual 
relationship of bone destruction between the cell types 
known as “the vicious cycle” [12]. In contrast, osteoblastic 
lesions are associated with tumor cells that stimulate 
osteogenesis [13, 14].
As with most solid tumors, early- stage OS displays 
significant regions of hypoxia, where resistant tumor cells 
reside, which results in tumor recurrence and metastasis, 
leading to treatment failure and poor outcomes. These 
hypoxic conditions found in tumor subregions are rarely 
observed in normal tissue; tumor hypoxia can therefore 
provide the basis for selective cancer therapy and there 
are a number of strategies currently being investigated to 
selectively target tumor cells in this hypoxic environment. 
Hypoxia- activated prodrugs (HAPs) selectively deliver 
cytostatic or cytotoxic agents to hypoxic subregions.
Evofosfamide (formerly TH- 302) is a hypoxia- activated 
prodrug composed of 2- nitroimidazole linked to bromo- 
isophosphoramide mustard (Br- IPM) [15]. The 
2- nitroimidazole component of evofosfamide serves as an 
oxygen sensor, releasing the crosslinking DNA- alkylating 
Br- IPM into the hypoxic regions of tumors. To date, 
evofosfamide has been investigated both as a stand- alone 
agent and in combination with chemotherapy and other 
targeted cancer drugs against numerous solid tumor types 
and blood cancers [16–18].
Proapoptotic Receptor Agonists (PARAs), either as 
monotherapy or in combination with other agents, are 
generally well- tolerated by patients with very few side 
effects [19] and although phase 1/1b studies provided 
encouraging preliminary results, findings from randomized 
Phase 2 studies failed to demonstrate significant clinical 
benefit [20–23]. Despite these clinical observations, there 
has been no investigation examining the anticancer efficacy 
of evofosfamide alone or in combination with either the 
Proapoptotic Receptor Agonists (PARAs) dulanermin 
(formerly known as Apo2L/TRAIL), or drozitumab for 
the treatment of osteosarcoma.
This study investigates the cytotoxic activity of evofos-
famide alone and in combination with dulanermin and 
drozitumab against human OS cells in vitro and in vivo, 
using a clinically relevant orthotopic mouse model of OS 
and on their subsequent lung metastases.
Materials and Methods
Cells
The human OS cell lines BTK- 143 and K- HOS were 
obtained from ATCC (Manassas, VA) and were authen-
ticated by DNA (STR) profiling. Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM), supple-
mented with 2 mmol/L glutamine, 100 IU/mL penicillin, 
160 μg/mL gentamicin, and 10% fetal bovine serum (Life 
Technologies, Carlsbad, CA) in a 5% CO2- containing 
humidified atmosphere. The generation of luciferase- tagged 
BTK- 143- TGL has been described previously [24].
Normal human osteoblasts (NHB) were obtained from 
bone marrow aspirations from the iliac crest of normal 
healthy donors or from the trabecular bone of osteoar-
thritic patients at joint replacement surgery, grown in 
αMEM (SIGMA, Saint Louis, Missouri) containing 
L- ascorbic acid 2- phosphate (Life Technologies, Carlsbad, 
CA) and 10% fetal bovine serum. Medium was then 
replaced at 4- day intervals, cells were then consequently 
subcultured by treatment with a (0.1%) (w/v) mixture 
of collagenase and dispase. In all experiments, cells from 
the first passage were used in all experiments.
Drugs
Threshold Pharmaceuticals (South San Francisco, CA) 
provided the evofosfamide powder which was dissolved 
in a sterile saline solution at a concentration of 
13.2 mmol/L. The Caspase Inhibitor- 1 ZVAD- fmk, was 
purchased from Calbiochem Inc. (La Jolla, CA). Both 
drozitumab and dulanermin were a gift from Dr Avi 
Ashkenazi, Genentech, Inc. (South San Francisco, CA). 
Affinity Pure Goat anti- human IgG Fcγ fragment was 
purchased from Jackson Immuno Research Laboratories 
Inc. (West Grove, PA).
Cell viability assay
To determine the cytotoxicity of evofosfamide on cell 
growth, 1 × 104 cells per well were seeded in 96- well 
microtiter plates and allowed to attach overnight. Cells 
were then treated with increasing concentrations of evo-
fosfamide (1–100 μmol/L) alone and in combination with 
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100 ng/mL of either dulanermin or drozitumab for 24 h 
under both hypoxic (1% O2) and normoxic conditions. 
Drozitumab was cross- linked with an anti- human IgG Fcγ 
for 30 min at 4°C prior to treatment before all in vitro 
experiments. Crystal Violet staining was used to determine 
cell viability and optical density was measured at 570 nm 
wavelength (OD570). Results of representative experiments 
are presented as the mean ± SD which were performed 
in triplicate and repeated at least three times.
Apoptosis analysis
Measurement of DEVD- caspase activity with and 
without caspase inhibitor 1, ZVAD- fmk
DEVD- caspase activity was assayed by cleavage of the 
fluorogenic substrate zDEVD- AFC and based on the pep-
tide sequence at the caspase- 3 cleavage site of poly (ADP- 
ribose) polymerase. Cells were grown in 96- well plates at 
a density of 1 × 104/well and treated for 24 h as indicated, 
washed once with PBS, and resuspended in 30 μL lysis 
buffer containing 5 mmol/L EDTA, 5 mmol/L Tris- HCl, 
and 10% Igepal (pH 7.5). Cell lysate containing 20 μg 
of protein was added to each well containing 8 μmol/L 
substrate in 1 mL fluorometric protease buffer which 
contained 10% sucrose, 50 mmol/L HEPES, 0.1% CHAPS 
(pH 7.4), 10 mmol/L DTT. Fluorescence was then quanti-
fied (Ex 400 and Em 505) after 4 h at room temperature 
using a BMG FLUOstar OPTIMA microplate reader. Results 
were expressed relative to the protein concentration of 
the sample, which was determined using a commercial 
BCA protein assay reagent from Thermo Fisher Scientific 
(Waltham, MA). Caspase Inhibitor 1, ZVAD- fmk, was 
resuspended at a concentration of 50 mM and added to 
the cells at 50 μmol/L alone, with evofosfamide at 
50 μmol/L, drozitumab + anti- human IgG Fcγ, or dulan-
ermin at 100 ng/mL.
Western blot analysis
Cells were treated with 50 μmol/L of evofosfamide, alone 
or in combination with 100 ng/mL of either dulanermin 
or drozitumab (cross- linked with an anti- human IgG Fcγ), 
under hypoxic (1% O2) and normoxic (21% O2) condi-
tions for 24 h and lysed in buffer containing 150 mmol/L 
NaCl, 10 mmol/L Tris- HCl (pH 7.6), 0.1% sodium dodecyl 
sulfate, 1% Triton X- 100, 2 mmol/L sodium vanadate, 
and a protease inhibitor tablet (Roche Diagnostics, 
Mannheim, Germany). Protein lysates were heated for 
10 min at 70°C and loaded under reducing conditions 
into 4–12% polyacrylamide gels for electrophoresis. 
Separated proteins were transferred to PVDF membranes 
(GE Healthcare, Buckinghamshire, UK) electrophoretically 
and blocked in PBS containing 5% blocking reagent (GE 
Healthcare, Buckinghamshire, UK) and 0.1% Tween 20 
for 1 h at room temperature.
Immunodetection was performed at 4°C overnight in 
blocking reagent/PBS, using the following primary anti-
bodies mAb anti- caspase- 8, pAb anti- caspase- 9, mAb anti- 
caspase- 3, and pAb anti- bid which were purchased from 
Cell Signaling Technology (Beverly, MA), pAb anti- 
Inhibitor of Apoptosis 2 (cIAP2), pAb anti- Inhibitor of 
Apoptosis 1 (cIAP1), pAb anti- XIAP, pAb death receptor 
4 (DR4), and pAb death receptor 5 (DR5) purchased 
from R&D systems, pAb anti- Poly- (ADP- Ribose) 
Polymerase (PARP) from Roche Diagnostics (Mannheim, 
Germany). Anti- actin mAb was used as a loading control 
and was purchased from SIGMA, Saint Louis, Missouri, 
USA. All primary antibodies were used at the dilutions 
suggested by their manufacturers. Membranes were then 
rinsed three times with PBS containing 0.1% Tween- 20 
and incubated for 1 h with a 1:5,000 dilution of anti- 
goat, anti- mouse, or anti- rabbit alkaline phosphatase- 
conjugated secondary antibodies (Thermo Fisher Scientific, 
Waltham, MA). The ECF substrate reagent kit (GE 
Healthcare, Buckinghamshire, UK) and the FluorImager 
(Molecular Dynamics Inc., Sunnyvale, CA) were used to 
visually assess and quantify the protein bands.
Animals
For a minimum period of 1 week prior to the com-
mencement of experimentation, 4- week- old female athymic 
mice were acclimatized to the animal housing facility under 
pathogen- free conditions (Institute of Medical and 
Veterinary Services Division, Gilles Plains, SA, Australia). 
Throughout the experiments, the general physical well- 
being and weight of animals were monitored. All experi-
mental procedures on animals were carried out with strict 
adherence to the guidelines and rules for the ethical use 
of animals in research and were approved by the Animal 
Ethics Committees of the Institute of Medical and 
Veterinary Science and the University of Adelaide, SA, 
Australia.
Intratibial injections of osteosarcoma cells
The BTK- 143- TGL OS cell line was cultured as described 
previously until 70–80% confluency was reached. Cells 
were removed from flasks with 2 mmol/L EDTA and 
resuspended at 1 × 105 cells per 10 μL PBS and kept on 
ice in an Eppendorf tube. The left tibia was wiped with 
70% ethanol and with the knee flexed, coupled to a 
Hamilton syringe, a 27 gauge needle was inserted through 
the tibial plateau and 1 × 105 BTK- 143- TGL cells resus-
pended in 10 μL of PBS were injected in the marrow 
space. As the control, all animals were injected with PBS 
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into the contralateral tibia. Mice were randomly assigned 
into groups of seven animals and 7 days after cancer cell 
transplantation, drug dosing started. Evofosfamide was 
administered via i.p injection once a day for 5 days fol-
lowed by 2 days of rest at 50 mg/kg body weight, whereas 
drozitumab was administered at 3 mg/kg i.p once a week 
until the end of the experiment.
In vivo bioluminescent imaging
The IVIS 100 Imaging system (Xenogen, Alameda, CA) 
was used weekly to perform noninvasive, whole body 
imaging to monitor the luciferase- expressing OS cell line 
BTK- 143- TGL in mice using 100 μL of the D- Luciferin 
(Xenogen Alameda, CA) solution at final dose of 3 mg/20 g 
mouse body weight, injected i.p. Mice were then gas- 
anesthetized with Isoflurane (Faulding Pharmaceuticals, 
Salisbury, SA, Australia). Images were acquired from the 
side angle for 0.5–30 sec (representative images are shown 
at 1 sec) and the Xenogen Living image (Igor Pro version 
2.5) software was used to capture and quantify photon 
emission from mice in photons/sec per cm2.
Microcomputed tomography ex vivo 
analysis
The SkyScan- 1072 high- resolution μCT Scanner (Kontich, 
Skyscan, Belgium) was operated at 80 kV, 120 μA, rota-
tion step 0.675, with a 0.5 mm Al filter and scan resolu-
tion of 5.2 μm/pixel was used to scan surgically resected 
limbs. Cross sections of the samples were reconstructed 
using a cone- beam algorithm (software Cone rec, Skyscan). 
The growth plate was identified using the 2D images 
obtained from the μCT scan and starting from the growth 
plate/tibial interface and moving down the tibia, 450 sec-
tions were selected for quantification. To determine 3D 
bone morphometric parameters (software CTAn, Skyscan), 
3D evaluation was performed on all data sets acquired 
by selecting total bone of the proximal tibia, the cross 
sections were reconstructed using a cone- beam algorithm 
(software Cone_rec, Skyscan). Files were then imported 
into CTAn software (Skyscan) for 3D analysis and 3D 
image generation. All images are viewed and edited using 
ANT visualisation software (Skyscan).
Data statistics and analysis
Experiments were performed in triplicate and data pre-
sented as mean ± SE. SigmaStat for Windows version 
3.0 (Systat Software, Inc., Port Richmond, CA) was used 
for all statistical analysis using the unpaired Student’s T 
test. Spearman Rank correlation coefficient was used to 
assess the association between two variables and 
comparisons between groups were assessed using a one- 
way ANOVA test. In all cases, P < 0.05 was considered 
statistically significant.
Results
Evofosfamide cooperates with drozitumab 
and dulanermin, displaying increased 
hypoxia- selective cytotoxicity against OS 
cells
Human OS cell lines K- HOS and BTK- 143 were assessed 
for their sensitivity to the cytotoxic activity of evofosfamide 
alone and in combination with a maximum dose of 100 ng/
mL of drozitumab or dulanermin for 24 h under normoxic 
(21% O2) and hypoxic (1% O2) conditions. In both OS 
cell lines as a single agent, evofosfamide had minimal tox-
icity under normoxic conditions. In contrast, under hypoxic 
conditions, evofosfamide dose dependently decreased cell 
viability in both OS cell lines, with 43% viability for the 
BTK- 143 cells and 65% viability for the K- HOS cells at 
25 μmol/L. Under normoxic conditions, both OS cell lines 
were resistant to the cytotoxic activity of drozitumab and 
dulanermin alone at 100 ng/mL. However, under hypoxic 
conditions, K- HOS cells were comparably more sensitive 
to the cytotoxic activity of both drozitumab and dulanermin 
alone (39 and 47% viability, respectively), whereas BTK- 143 
cells were relatively resistant (94 and 77% viability).
Both OS cell lines showed a significant increase in 
cytotoxicity when either drozitumab or dulanermin were 
combined with evofosfamide in a dose- dependent manner 
under hypoxic conditions, resulting in 95% loss of viability 
at 25 μmol/L for both OS cell lines (Fig. 1A). In contrast, 
primary normal human osteoblasts, cultured from patients 
undergoing hip replacement surgery, were resistant to the 
cytotoxic activity of evofosfamide at 100 μmol/L in com-
bination with either drozitumab or dulanermin under 
similar conditions (Fig. 1B).
Evofosfamide- mediated OS cytotoxicity is 
only partly caspase 3- dependent
The increase in caspase- 3 activation with 50 μmol/L of 
evofosfamide treatment under hypoxic conditions alone 
and in combination with drozitumab or dulanermin 
(100 ng/mL) was associated with a decrease in cell viability. 
However, co- administration with ZVAD- fmk, a pan- 
caspase inhibitor did not prevent the reduction in cell 
viability caused by evofosfamide in both OS cell lines 
under hypoxic conditions, despite irreversibly inhibiting 
the activity of caspase- 3 (Fig. 2), suggesting that the 
mechanisms involved in evofosfamide- mediated cytotoxic-
ity are not entirely caspase- dependent.
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However, ZVAD- fmk completely reversed the cytotoxic 
activity of both drozitumab and dulanermin in both OS cell 
lines, indicating that the cytotoxicity of these PARAs against 
these OS cells is largely caspase dependant, this being in line 
with the well- established mechanism of action of these proa-
poptotic agents. When either drozitumab or dulanermin was 
combined with evofosfamide and the caspase inhibitor ZVAD- 
fmk was added, there was a significant reduction in cytotoxicity 
against both OS cell lines when compared to the combination 
of these drugs without ZVAD- fmk.
The molecular determinants involved in evofosfamide- 
mediated apoptotic signaling alone and in combination 
with drozitumab or dulanermin were characterized (Fig. 3). 
Evofosfamide alone treatment at 50 μmol/L under hypoxic 
conditions (1% O2), for 24 h activated the caspase cascade 
with robust cleavage of the initiator caspase- 8, caspase- 9, 
caspase- 3, and cleavage of poly ADP- ribose polymerase 
(PARP) which was determined by the detection of the 
cleaved products in all these antibodies. The mitochondrial 
proapoptotic Bcl- 2 family protein BID, inhibitor of apop-
tosis proteins cIAP1, cIAP2, and XIAP, however, remained 
unchanged. The combination of evofosfamide with dulan-
ermin or drozitumab in both OS cell lines resulted in 
increased processing of caspases 8, 9, 3, and PARP. 
Importantly, combination treatment under hypoxia resulted 
in the robust cleavage of BID, likely resulting in the ampli-
fication of apoptotic signaling. Interestingly, we observed 
a significant decrease in the levels of inhibitor of apoptosis 
proteins cIAP1, cIAP2, and XIAP in the K- HOS cell line. 
The levels of cIAP2 in the BTK- 143 remained unchanged.
Under hypoxic conditions, evofosfamide alone and in 
combination with either dulanermin or drozitumab upregu-
lated the death receptor DR5 in both cell lines. In the 
K- HOS cell line, which was more sensitive to dulanermin 
Figure 1. Activity of evofosfamide in combination with drozitumab and dulanermin against OS cells and primary normal human osteoblasts in vitro. 
(A) OS cell lines BTK- 143 and K- HOS were seeded in 96- well plates at 1 × 104 cells per well and treated with increasing doses of evofosfamide alone 
and in combination with either drozitumab or dulanermin under normoxic (21% O2) and hypoxic (1% O2) conditions for 24 h. (B) Primary normal 
human osteoblasts were resistant to evofosfamide and the combination with either drozitumab or dulanermin under the same conditions. Cell 
viability was assessed by crystal violet staining. Data points show means of quadruplicate results from a representative experiment, repeated at least 
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Figure 2. The cytotoxic activity of dulanermin and drozitumab is caspase- dependent, whereas evofosfamide is not. OS cell lines were seeded in 96- 
well plates at 1 × 104 cells per well and treated with evofosfamide alone at 50 μmol/L and with drozitumab IgG 100 ng/mL, dulanermin 100 ng/mL 
or coincubated with the broad specificity caspase inhibitor z- VAD- fmk (50 μmol/L). To exclude possible toxic effects of the inhibitor, cells were also 
treated with the inhibitor alone under normoxic and hypoxic (1% O2) conditions. Cell lysates were used to determine caspase- 3- like activity, using the 
caspase- 3- specific fluorogenic substrate, zDEVD- AFC and cell viability was assessed via crystal violet staining. Data points show means of quadruplicate 
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and drozitumab when compared to the BTK- 143 cell line, 
dulanermin and drozitumab alone also upregulated DR5 
as single agents under both normoxic and hypoxic condi-
tions. There were no significant differences in the expres-
sion of DR4 following treatment.
Cytotoxic activity of evofosfamide and 
drozitumab against osteosarcoma- induced 
bone destruction
Drozitumab was specifically chosen as opposed to dulan-
ermin in this preclinical study due to its ability to spe-
cifically bind to DR5 and not the TRAIL decoy receptors. 
In addition, drozitumab has a longer half- life when com-
pared to dulanermin [25].
To investigate the anticancer efficacy of drozitumab and 
evofosfamide against osteosarcoma progression and metas-
tasis, an orthotopic model of OS was used in which luciferase- 
tagged BTK- 143- TGL cells were directly transplanted into 
the tibial marrow cavity of female athymic nude mice and 
accurately monitored and quantified using noninvasive bio-
luminescence imaging over a 28–day- period [24]. Treatment 
with drozitumab, evofosfamide, or the combination of both 
agents commenced 7 days after the intratibial OS cell injec-
tions. All vehicle- treated animals showed an increase in mean 
photon emission exponentially, which indicated an increase 
in tumor burden palpable from day 7 onward, reaching a 
maximum signal at day 28, at which point animals were 
humanely killed. In contrast, treatment with evofosfamide 
or drozitumab showed a reduction in tumor burden over 
Figure 3. Apoptotic signaling of evofosfamide, dulanermin, and drozitumab against OS cells. OS cells were seeded at 2 × 106 per T25 flask and were 
treated with evofosfamide at 50 μmol/L, dulanermin and drozitumab at 100 ng/mL under normoxic (21% O2) and hypoxic (1% O2) conditions. After 
24 h, cells were lysed and protein was collected. Cell lysates were analyzed by polyacrylamide gel electrophoresis and transferred to PVDF membranes 
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the same period in all animals. Importantly, the combina-
tion demonstrated a far greater anticancer efficacy in the 
bone (Fig 4A and B). The tibiae of all mice were dissected 
at the end of the experiment and the qualitative and quan-
titative assessment of bone destruction was analyzed using 
high resolution μCT (Fig 4C). In the vehicle- treated animals, 
extensive osteolysis was clearly evident such that the net 
loss in bone volume (BV) was 69% in the left tumor- bearing 
tibiae when compared to the contralateral nontumor bearing 
right tibiae.
Although tumor burden was reduced by evofosfamide 
treatment, this did not prevent bone destruction such 
that the extent of osteolysis was not significantly different 
when compared to the vehicle- treated group. Remarkably, 
treatment with drozitumab alone resulted in extensive 
bone remodeling, resulting in a gain of bone volume of 
27% when compared to the untreated right tibia. Micro- CT 
analysis showed extensive bone remodeling that was 
noticeable under the growth plate and extended down 
the length of the tibia where the tumor resided. Tumor 
healing in the treatment of osteosarcoma in patients if 
often correlated with a significant increase in calcification, 
which would account for the increase in calcification in 
the tumor affected tibia of mice treated with drozitumab 
[26]. In animals treated with the combination of dro-
zitumab and evofosfamide, the tibia had a normal appear-
ance due to the full mineralization of the cortical bone, 
demonstrating additional protection of the bone archi-
tecture, less calcification, and more advanced bone remod-
eling, such that the net gain of BV was reduced to 6%.
Ex vivo bioluminescence imaging showed no differences 
between the treated groups (three out of seven mice) in 
the number of mice that developed lung metastases which 
may be due to cancer cells entering into the blood stream 
and metastasizing to the lung during the 7 days before 
treatment. However, the tumor burden in the lungs of 
the mice with metastases which was measured as a func-
tion of bioluminescence signal showed a reduction in tumor 
growth with evofosfamide treatment. In addition, drozitu-
mab maintained its cytotoxicity against metastatic OS cells 
in the lungs, which led to the tumor burden being reduced 
in both the drozitumab and combination groups (Fig 4D).
Effect of evofosfamide on bone metabolism
Our experimental approach also provides an opportunity 
to assess the normal bone parameters after treating the 
mice with evofosfamide, drozitumab, and the combina-
tion of both. After 3 weeks of treatment, the use of 
high- resolution micro- CT analysis to compare the con-
tralateral nontumor- bearing tibiae of treated and untreated 
animals showed no differences in any of the microarchi-
tectural bone morphometric parameters, which included 
total bone volume, bone surface, trabecular number, 
trabecular thickness, or trabecular spacing (Table 1).
Discussion
In addition to surgical intervention, chemotherapeutic 
agents such as doxorubicin, etoposide, cisplatin, and cyclo-
phosphamide used alone, or in combination have signifi-
cantly improved overall survival for patients with OS. 
Yet, despite these improvements in treating the primary 
tumor, a large number of patients with OS eventually 
develop lung metastases, even after surgical excision and 
conventional chemotherapy. There is a need to therefore, 
develop safe and new approaches for OS treatment 
[27–29].
It must be noted that when compared to other tissues, 
the bone marrow and in particular the hematopoietic 
niche close to the endosteal surface is hypoxic, which is 
required for normal hematopoiesis to occur [30]. Unlike 
soft tissue tumors, OS can also adapt to this hypoxic 
bone microenvironment. The ability to target OS in this 
hypoxic bone environment is therefore an important fea-
ture that evofosfamide has over other cancer therapies. 
In addition, conventional chemotherapeutics are usually 
cytotoxic to normal bone cells in the bone marrow, an 
important goal of anticancer treatment is to selectively 
target cancer cells but not normal bone cells.
A combinatorial approach using agents with additive 
or synergistic cytotoxic activities are appealing because 
they allow lower drug doses to be used, which reduce 
harmful side effects, particularly in the bone. Consistent 
with our previous published data [31, 32] under nor-
moxic conditions, evofosfamide alone resulted in mini-
mal toxicity against OS, whereas under hypoxic 
conditions, evofosfamide decreased OS cell viability. In 
addition, under normoxic conditions, both OS cell lines 
were resistant to the cytotoxic activity of drozitumab 
and dulanermin as single agents. However, under hypoxic 
conditions, K- HOS cells were comparably more sensi-
tive to the cytotoxic activity of both drozitumab and 
dulanermin alone, while BTK- 143 cells were relatively 
resistant. This resensitization of the K- HOS cell line 
to both these drugs may be attributed to the hypoxic 
conditions providing an additional stress mechanism, 
which in turn activate the extrinsic and intrinsic apop-
totic pathways for this OS cell line. Importantly, while 
both OS cell lines are resistant to the treatments under 
normoxic conditions, under hypoxic conditions, this 
cytotoxic activity was further increased when evofos-
famide was co administered with either drozitumab or 
dulanermin under hypoxic conditions. The combination 
of the chemotherapeutic agents’ drozitumab and dulan-
ermin with evofosfamide was not toxic to either normal 
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human bone cells in vitro or normal bone metabolism 
in vivo, corroborating with previous studies which 
demonstrate that these agents individually are nontoxic 
to normal bone. [24, 31, 33]. These results highlight 
not only the hypoxic selectivity of evofosfamide, but 
also the specific tumor selectivity of both evofosfamide 
and PARAs.
In the search for more effective treatments for OS, PARAs 
including recombinant dulanermin and the agonistic anti-
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overlapping signaling pathways, whereas evofosfamide 
induces apoptosis mainly through caspase- independent 
mechanisms as described previously [32]. As a result, the 
combination of PARAs and evofosfamide were considerably 
more cytotoxic to tumor cells that resist cytotoxic activity 
through a single pathway, where inhibiting caspase activity 
to prevent the activity of both drozitumab and dulanermin 
still resulted in both OS cell lines under hypoxic condi-
tions being sensitive to the cytotoxic activity of evofosfa-
mide. This is also reflected by the activation of caspase- 8, 
caspase- 9, caspase- 3, PARP, cleavage of Bid, a member of 
the Bcl- 2 family protein, and the downregulation of c- IAP1 
when evofosfamide was combined with dulanermin or 
drozitumab as well as both PARAs activating the extrinsic 
pathway by the upregulation of DR5.
Based on our in vitro results, the therapeutic potential 
of evofosfamide was expected to be greatest in combina-
tion with adjuvant cytotoxic chemotherapy. When trans-
planted into the tibial marrow cavity of mice, BTK- 143 
cells are highly osteolytic and this results in extensive 
bone destruction and the development of metastases to 
the lung 3–4 weeks post cancer cell transplantation. This 
in vivo model mimics OS activity in the bone as seen 
in patients with the disease and is ideal for determining 
the potential of drug treatment on cancer growth in the 
bone as well as cancer- induced bone destruction [24, 
31]. The activity of evofosfamide in combination with 
drozitumab was tested in this context, in a preclinical 
model of OS progression and development for the fol-
lowing reasons. In contrast to dulanermin, which has a 
short bioavailability of 30 min, which requires daily treat-
ment for patients and the inability to bind to death- 
inducing TRAIL receptors in various cancer types, 
preferring to bind with the decoy TRAIL receptors [34, 
35], drozitumab is a fully agonistic human monoclonal 
antibody that specifically binds to and activates DR5 in 
the same manner as dulanermin [24]. Drozitumab has 
a half- life ranging from several days to weeks and has 
been developed to specifically target DR5 [36] and not 
the TRAIL decoy receptors. In addition, circulating 
Fragment Crystalline Gamma (Fcγ) receptors expressed 
on the surface of various immune cells [37, 38], crosslink 
with drozitumab which leads to enhanced antibody- 
dependent, cell- mediated cytotoxicity (ADCC) [39], result-
ing in immune cell activation leading to recruitment of 
other Fcγ receptor- expressing cells to the tumor micro-
environment [35, 39]. The apoptotic tumor cells are then 
phagocytosed by the activated Fcγ receptor- expressing 
Figure 4. Drozitumab cooperates with evofosfamide to reduce OS intratibial tumors in vivo. BTK- 143- TGL cells were injected directly into the tibial 
marrow cavity of 4- week- female athymic mice, allowed to establish for 7 days, as described in the methods, mice were imaged weekly using the 
Xenogen IVIS 100 bioluminescence imaging system. (A). Representative whole body bioluminescent images of a single mouse from each group during 
the course of the experiment are shown. (B). The line graph, showing average tumor signal over time, expressed as mean photon counts per second 
during the course of the experiments are shown. Animals receiving treatment with evofosfamide and drozitumab as single agents showed a significant 
delay in tumor growth. In addition, all mice receiving the combination of evofosfamide and drozitumab showed a further delay of tumor growth when 
compared with each agent individually. (C). Quantitative assessment of Total bone loss (%) comparing the tumor- bearing tibiae of each group to the 
contralateral tibiae and the qualitative 3- D micro CT images show the osteolytic nature of the BTK- 143- TGL cell line, which was reduced by drozitumab 
alone and the combination of evofosfamide and drozitumab. (D). Average lung tumor growth was assessed via bioluminescence showing evofosfamide, 
drozitumab, and the combination of both agents caused a reduction in lung tumor growth of the BTK- 143- TGL cell line when compared to the vehicle 
group. Data shown in each case are the average bioluminescent imaging from all animals in that group: points are means ± SEM.
Table 1. Comparison of bone morphometric parameters of contralateral nontumor- injected tibiae from vehicle, evofosfamide- , drozitumab- , evofos-
famide + drozitumab- treated animals.
Parameters Vehicle control Evofosfamide Drozitumab Evofosfamide + Drozitumab
Mean SE Mean SE Mean SE Mean SE
Bone volume(mm3) 2.34 0.05 2.27 0.07 2.31 0.14 2.30 0.11
Bone surface (mm2) 191.68 4.07 194.55 4.94 188.71 6.58 195.52 10.91
Intersection surface (mm2) 0.36 0.03 0.32 0.04 0.38 0.03 0.36 0.09
Trabecular space (mm) 1.53 0.02 1.49 0.04 1.57 0.04 1.45 0.03
Trabecular number (1/mm) 0.16 0.07 0.18 0.01 0.16 0.02 0.20 0.02
Trabecular thickness (mm) 0.05 0 0.05 0 0.06 0 0.05 0
Trabecular pattern factor (1/mm) 24.24 1.37 21.17 1.79 23.90 0.77 22.05 1.05
Structure model index 2.14 0.04 2.04 0.23 2.08 0.03 1.92 0.06
Bone volume, bone surface, intersection surface, trabecular space, trabecular number, trabecular thickness, trabecular pattern factor, and structure 
model index were measured by three- dimensional analysis of μCT images of the contralateral tibial bone.
Results are expressed as mean ± SE. Significance of results is with respect to untreated animals obtained using Student’s t test.
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immune cells [40], further enhancing the cytotoxic activity 
of drozitumab against cancer.
The activity of drozitumab against OS in bone has yet 
to be reported and in addition, this OS cell line is relatively 
resistant to drozitumab in vitro, allowing the detection of 
any synergistic or additive activity to be easily observed.
As a single agent, evofosfamide had limited impact in 
reducing tumor growth in the tibia or protecting the tibia 
from the cancer- induced bone destruction caused by this 
highly aggressive osteolytic cell line.
The cytotoxic activity displayed by drozitumab in vivo 
contradicts the resistance of this human osteosarcoma 
shown in vitro. A possible explanation to account for the 
increase in cytotoxicity of drozitumab in vivo is the cir-
culation of Fcγ receptors expressed by leukocytes in mice. 
The engagement of leukocyte Fcγ receptors by antibody- 
antigen complexes leads to an enhanced antibody- 
dependent, cell- mediated cytotoxicity (ADCC) [39], which 
can interact more efficiently with the DR5 agonistic anti-
body drozitumab when compared to artificial Fc crosslink-
ing in vitro, leading to improved cytotoxicity against the 
human osteosarcoma in the tibia and lungs of the mice.
The combination of both evofosfamide and drozitumab 
had a profound effect in preventing growth of the tumor 
within the tibia which also translated to increased bone 
protection and a reduction in tumor burden in the lung. 
This may be related to the ability of evofosfamide to 
upregulate DR5 expression under hypoxic conditions, 
resulting in increased sensitivity to Drozitumab as observed 
in previous studies [41]. In addition, each drug specifi-
cally targets tumor regions of different oxygen tensions 
accordingly.
PARAs including drozitumab and dulanermin have been 
tested either alone or in combination with other agents 
in phase I and II clinical trials [19], with little clinical 
benefit observed to date which has led to the discontinu-
ation of the development of PARAs in many cases [42]. 
However, none of these clinical trials have examined the 
anticancer efficacy of PARAs against cancers in the bone 
such as OS.
Evofosfamide is currently being evaluated both as 
monotherapy and in combination with conventional 
chemotherapy and radiotherapy in numerous phase I and 
phase II clinical trials against a variety of cancer types. 
To date, two phase 3 trials targeting unresectable or 
metastatic soft tissue sarcoma NCT01440088 and unre-
sectable pancreatic adenocarcinoma NCT01746979 [43] 
failed to meet their primary endpoint of improving overall 
survival with statistical significance. Nonetheless, from 
the observations in phase I and II clinical trials of evo-
fosfamide and PARAs, and from the results presented in 
this study, which indicate that these compounds are 
nontoxic to normal bone metabolism suggest that OS 
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